{
    "pmcid": "8193598",
    "qa_pairs": {
        "What is a common target for nanobodies in their mechanism of action against SARS-CoV-2?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.",
            "The nucleocapsid protein of SARS-CoV-2.",
            "The membrane protein of SARS-CoV-2.",
            "The envelope protein of SARS-CoV-2."
        ],
        "What is one of the key advantages of nanobodies over conventional antibodies in therapeutic applications against SARS-CoV-2?": [
            "Nanobodies can be administered via inhalation due to their small size.",
            "Nanobodies have a longer half-life in circulation than conventional antibodies.",
            "Nanobodies are more expensive to produce than conventional antibodies.",
            "Nanobodies are derived from human antibodies, making them more compatible with human immune systems."
        ],
        "What is one reason nanobodies are considered promising candidates for therapeutic interventions against SARS-CoV-2?": [
            "They offer a versatile platform for developing treatments tailored to emerging variants.",
            "They are derived from human antibodies, ensuring compatibility with human immune systems.",
            "They have a longer half-life in circulation compared to conventional antibodies.",
            "They are more expensive to produce, ensuring high-quality production standards."
        ],
        "Which nanobody demonstrated cross-reactivity between SARS-CoV and SARS-CoV-2 S proteins and was isolated from a llama phage display library?": [
            "VHH-72",
            "3F11",
            "H11",
            "NIH-CoVnb-112"
        ],
        "Which nanobody was identified from a phage display library using the recombinant RBD of the SARS-CoV-2 S protein and showed potent neutralization of the virus?": [
            "3F11",
            "VHH-72",
            "H11",
            "NIH-CoVnb-112"
        ]
    }
}